JLB & Associates Inc. Sells 3,469 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

JLB & Associates Inc. lowered its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 4.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 78,132 shares of the company’s stock after selling 3,469 shares during the quarter. JLB & Associates Inc. owned about 0.06% of Henry Schein worth $5,407,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. ING Groep NV acquired a new position in shares of Henry Schein during the third quarter valued at about $63,226,000. Holocene Advisors LP bought a new position in Henry Schein in the 3rd quarter valued at about $58,319,000. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Henry Schein in the 3rd quarter valued at about $43,740,000. Southpoint Capital Advisors LP boosted its stake in Henry Schein by 30.0% during the 3rd quarter. Southpoint Capital Advisors LP now owns 2,600,000 shares of the company’s stock valued at $189,540,000 after purchasing an additional 600,000 shares during the last quarter. Finally, Bank of Montreal Can increased its holdings in Henry Schein by 365.6% during the 3rd quarter. Bank of Montreal Can now owns 711,487 shares of the company’s stock worth $52,095,000 after purchasing an additional 558,689 shares in the last quarter. Institutional investors own 96.62% of the company’s stock.

Henry Schein Stock Up 0.3 %

Henry Schein stock opened at $78.05 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $9.73 billion, a P/E ratio of 32.12, a P/E/G ratio of 2.12 and a beta of 0.91. The firm has a 50 day moving average price of $74.13 and a 200-day moving average price of $72.15. Henry Schein, Inc. has a twelve month low of $63.67 and a twelve month high of $82.63.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Wells Fargo & Company assumed coverage on Henry Schein in a report on Friday, February 14th. They issued an “equal weight” rating and a $80.00 target price on the stock. Jefferies Financial Group raised their price objective on Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, January 23rd. Barrington Research upped their target price on shares of Henry Schein from $82.00 to $90.00 and gave the stock an “outperform” rating in a research note on Thursday, January 30th. Mizuho started coverage on shares of Henry Schein in a report on Wednesday, December 4th. They issued a “neutral” rating and a $75.00 target price for the company. Finally, StockNews.com upgraded shares of Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Henry Schein has a consensus rating of “Moderate Buy” and an average target price of $80.09.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.